Biocon Shares Gained 2 Percent After The Company And Sandoz A Division

Biocon shares gained 2 percent after the company and Sandoz, a division of Swiss-pharmaceutical major Novartis, said they have entered into a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients across the globe.

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally.

Sandoz will lead commercialization in North America and the European Union, while Biocon will lead commercialization in the rest of the world.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory